https://doi.org/10.55788/a67349e8
“As you may know, cutaneous lupus is the most common manifestation of systemic lupus and delays in treatment or inadequate control lead to alopecia, scarring, and permanent pigmentary changes,” Dr Daniel Montes (University of Wisconsin, WI, USA) stated as background [1]. He further explained that although belimumab is already approved for systemic lupus erythematosus, knowledge gaps remain.
The presented meta-analysis was undertaken to gain insights into the efficacy of the B-cell activation inhibitor belimumab concerning predominant cutaneous manifestations of lupus and time to therapy response. The primary endpoint looked at clinical response concerning the cutaneous domain of the British Isles Lupus Assessment Group score (BILAG) in patients with or without belimumab. It was defined as a change from BILAG A/B at baseline to BILAG B-E after 52 weeks. “Additionally, we calculated a pooled odds ratio (OR) at each 4-week consecutive interval across 52 weeks to trend the time to clinical response in belimumab users,” Dr Montes informed. Based on the PRISMA guidelines, 13 studies were included in the meta-analysis, 6 of them randomised controlled trials.
After 1 year, the likelihood of clinical response in those on belimumab was 44% greater than in non-users (OR 1.44; P<0.0001), while the overall response rate was 55% when also observational studies were comprised. “We noted that the first significant clinical response in belimumab users was at week 20, and this was sustained to week 52, where the peak response was seen,” Dr Montes underlined. The OR of having a cutaneous flare was 0.51 (P=0.007), reflecting about half the probability of a flare for belimumab users.
“Our study found that belimumab is an effective biological therapy for patients with cutaneous lupus with or without systemic disease, but it can take up to 20 weeks to achieve a clinically significant response. Thus, belimumab should not be prematurely discontinued,” Dr Montes concluded.
- Montes D. Significant improvement in cutaneous lupus erythematosus with or without systemic lupus erythematosus with belimumab use – a systematic review and meta-analysis. 0348, ACR Convergence 2022, 10–14 November, Philadelphia, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies Next Article
TYK2 inhibition shows potential as a treatment for SLE »
« No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies Next Article
TYK2 inhibition shows potential as a treatment for SLE »
Table of Contents: ACR 2022
Featured articles
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome?
Early treatment: a key to improved outcomes in polyarticular JIA
ACR 2022 Congress Round-Up
Glucocorticoids in rheumatic diseases: Is there a skeletal sparing dose?
Bimekizumab: Robust 1-year results in treating psoriatic arthritis
Stimulation of PD-1: a new concept to treat RA
Denosumab in erosive hand arthritis: Structure repair of interphalangeal joints seems possible
High retention rates after switching between infliximab biosimilars
New analysis assesses the safety of tofacitinib regarding extended MACE
Lack of vaccination results in a higher frequency of pre-term births in pregnant women with rheumatic disease and COVID-19
Ankylosing spondylitis: Combining biologics with NSAID does not imply reduced radiographic progression
Diet and exercise programme: a successful OA strategy in a community-based setting
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome?
A novel risk score helps identify interstitial lung disease in patients with systemic sclerosis
Early treatment: a key to improved outcomes in polyarticular JIA
TYK2 inhibition shows potential as a treatment for SLE
Belimumab efficacious in cutaneous lupus erythematosus
No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies
Related Articles
February 4, 2020
Treatment decisions should not be guided by ultrasound findings
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com